Filtered By:
Source: European Heart Journal
Condition: Diabetes

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 31 results found since Jan 2013.

Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease
Conclusions</div>Compared to PCI, the effects of CABG on long-term risks for MACCE observed in the FREEDOM trial are preserved among patients with mild to moderate CKD.</span>
Source: European Heart Journal - August 28, 2016 Category: Cardiology Source Type: research

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500  000 patients with Type 2 diabetes mellitus
ConclusionCardiovascular disease-free life expectancy and effects of lifelong prevention in terms of CVD-free life-years gained can be estimated for people with T2DM using readily available clinical characteristics. Predictions of individual-level treatment effects facilitate translation of trial results to individual patients.
Source: European Heart Journal - January 9, 2019 Category: Cardiology Source Type: research

Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial
ConclusionRoutine ingestion by hypertensive patients of ≥1 prescribed BP-lowering medications at bedtime, as opposed to upon waking, results in improved ABP control (significantly enhanced decrease in asleep BP and increased sleep-time relative BP decline, i.e. BP dipping) and, most importantly, markedly diminished occurrence of major CVD events.Trial registrationClinicalTrials.gov, number NCT00741585. 
Source: European Heart Journal - October 22, 2019 Category: Cardiology Source Type: research

The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk
Conclusions These findings suggest that CAD/MI-associated risk alleles play an aetiological role in different types of atherosclerotic disease.
Source: European Heart Journal - October 1, 2013 Category: Cardiology Authors: Tragante, V., Doevendans, P. A. F. M., Nathoe, H. M., van der Graaf, Y., Spiering, W., Algra, A., de Borst, G. J., de Bakker, P. I. W., Asselbergs, F. W., on behalf of the SMART study group Tags: Coronary artery disease Source Type: research

Trends in age-specific coronary heart disease mortality in the European Union over three decades: 1980-2009
Conclusion There is limited evidence to support the hypothesis that CHD mortality rates in younger age groups in the member states of the EU have been more likely to plateau than in older age groups. There are, however, substantial and persistent inequalities between countries. It remains vitally important for the whole EU to monitor and work towards reducing preventable risk factors for CHD and other chronic conditions to promote wellbeing and equity across the region.
Source: European Heart Journal - October 14, 2013 Category: Cardiology Authors: Nichols, M., Townsend, N., Scarborough, P., Rayner, M. Tags: Coronary artery disease Source Type: research

Cardiovascular mortality in relation to birth weight of children and grandchildren in 500 000 Norwegian families
Conclusion Associations between CVD mortality in all four grandparents and grandchild birth weight exist, and while genetic and environmental factors may contribute to these, it appears that there is an important role for maternal smoking during pregnancy (and associated paternal smoking) in generating these associations. For diabetes, however, it appears that intrauterine environmental influences and genetic factors contribute to the transgenerational associations.
Source: European Heart Journal - November 21, 2013 Category: Cardiology Authors: Naess, O., Stoltenberg, C., Hoff, D. A., Nystad, W., Magnus, P., Tverdal, A., Davey Smith, G. Tags: Prevention and epidemiology Source Type: research

Prognostic models for stable coronary artery disease based on electronic health record cohort of 102 023 patients
Conclusion These validated prognostic models could be used in clinical practice to support risk stratification as recommended in clinical guidelines.
Source: European Heart Journal - April 1, 2014 Category: Cardiology Authors: Rapsomaniki, E., Shah, A., Perel, P., Denaxas, S., George, J., Nicholas, O., Udumyan, R., Feder, G. S., Hingorani, A. D., Timmis, A., Smeeth, L., Hemingway, H. Tags: Coronary artery disease Source Type: research

Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study
Conclusion For type 2 diabetes, the MHO phenotype is associated with lower risk than the metabolically unhealthy obese, but for CVD the risk is as elevated in both obesity phenotypes.
Source: European Heart Journal - March 1, 2015 Category: Cardiology Authors: Hinnouho, G.-M., Czernichow, S., Dugravot, A., Nabi, H., Brunner, E. J., Kivimaki, M., Singh-Manoux, A. Tags: Prevention and epidemiology Source Type: research

Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence
Conclusion Regardless of recent advances in PAD treatment, current outcomes remain poor especially in CLI. Despite overwhelming evidence for reduction of limb loss by revascularization, CLI patients still received significantly less angiographies and revascularizations.
Source: European Heart Journal - April 14, 2015 Category: Cardiology Authors: Reinecke, H., Unrath, M., Freisinger, E., Bunzemeier, H., Meyborg, M., Luders, F., Gebauer, K., Roeder, N., Berger, K., Malyar, N. M. Tags: Peripheral artery disease Source Type: research

Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Type 2 diabetes mellitus (T2DM) is characterized by multiple pathophysiologic abnormalities. With time, multiple glucose-lowering medications are commonly required to reduce and maintain plasma glucose concentrations within the normal range. Type 2 diabetes mellitus individuals also are at a very high risk for microvascular complications and the incidence of heart attack and stroke is increased two- to three-fold compared with non-diabetic individuals. Therefore, when selecting medications to normalize glucose levels in T2DM patients, it is important that the agent not aggravate, and ideally even improve, cardiovascular ri...
Source: European Heart Journal - September 7, 2015 Category: Cardiology Authors: Ferrannini, E., DeFronzo, R. A. Tags: Clinical update Source Type: research

Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure
Left ventricular ejection fraction (LVEF) has been the central parameter used for diagnosis and management in patients with heart failure. A good predictor of adverse outcomes in heart failure when below ~45%, LVEF is less useful as a marker of risk as it approaches normal. As a measure of cardiac function, ejection fraction has several important limitations. Calculated as the stroke volume divided by end-diastolic volume, the estimation of ejection fraction is generally based on geometric assumptions that allow for assessment of volumes based on linear or two-dimensional measurements. Left ventricular ejection fraction is...
Source: European Heart Journal - May 31, 2016 Category: Cardiology Authors: Cikes, M., Solomon, S. D. Tags: Clinical update Source Type: research

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
Patients with type 2 diabetes mellitus (T2D) exhibit an increased risk for cardiovascular (CV) events. Hyperglycaemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little to no impact on reducing CV risk, especially in patients with a long duration of T2D and prevalent CV disease (CVD). Sodium glucose cotransporter-2 (SGLT2) inhibitors are a novel class of anti-hyperglycaemic medications that increase urinary glucose excretion, thus improving glycaemic control independent of insulin. The recently published CV outc...
Source: European Heart Journal - November 16, 2016 Category: Cardiology Authors: Marx, N., McGuire, D. K. Tags: Clinical update Source Type: research

Impact of the SYNTAX scores I and II in patients with diabetes and multivessel coronary disease: a pooled analysis of patient level data from the SYNTAX, PRECOMBAT, and BEST trials
ConclusionsDifferences in 5 years outcomes following PCI and CABG for patients with MVD and diabetes were influenced by anatomic complexity as measured by the SYNTAX score. The SYNTAX score II mortality prediction model showed similar performance regardless of the diabetes status.
Source: European Heart Journal - April 18, 2017 Category: Cardiology Source Type: research

A Swiss National Strategy for 2017 –2024
A Swiss National Strategy for Cardiovascular disease, Stroke, and Diabetes for the next 7  years has been produced through a joint initiative of 26 National Cardiovascular Societies and the Swiss Heart Foundation 
Source: European Heart Journal - November 7, 2017 Category: Cardiology Source Type: research

Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk
ConclusionsIn patients with diabetes and elevated CV risk, even after extensive adjustment for underlying disease burden, there was a persistent association for low DBP with subclinical myocardial injury and risk of MI.
Source: European Heart Journal - January 31, 2018 Category: Cardiology Source Type: research